Efficacy and Safety of Intravenous Valproate for Status Epilepticus: A Systematic Review

Eugen Trinka · Julia Höfler · Alexander Zerbs · Francesco Brigo

Published online: 8 May 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract

Introduction The effectiveness of valproate (VPA) in the treatment of focal and generalized epilepsies is well established. The drug has a wide spectrum of action, good tolerability, and has been available as an injectable formulation since 1993. Despite the lack of class A evidence, it has been used extensively in various forms of status epilepticus (SE).

Aim Our aim was to present a systematic review of data from randomized and non-randomized controlled trials to evaluate the efficacy and safety of intravenous VPA for the treatment of SE.

Methods Data sources included MEDLINE, back tracing of references in pertinent studies, and contact with the manufacturer of VPA (Sanofi-Aventis).

Results Overall, the search strategy yielded 433 results (425 MEDLINE, seven congress abstracts, one unpublished study); after excluding duplicate publications and case reports, 30 studies were identified (the earliest was published in 1993, the most recent in 2012); ten were controlled (six randomized controlled trials, four non-randomized controlled studies), and 20 uncontrolled trials (eight prospective observational studies, 12 retrospective case series). The cumulative literature describes the experiences of 860 patients with various forms of SE treated with intravenous VPA. The overall response rate to abrogate SE was 70.9 % (601/848; 95 % confidence interval [CI] 67.8–73.9). Response rates to intravenous VPA were better in children than in adults and did not differ between the SE types. The most commonly reported effective doses were between 15 and 45 mg/kg in bolus (6 mg/kg/min) followed by 1–3 mg/kg/h infusion. Safety studies of intravenous VPA administration in patients with SE showed a low incidence of adverse events overall (<10 %), mainly dizziness, thrombocytopenia, and mild hypotension, which was independent of infusion rates. Of note, good cardiovascular and respiratory tolerability was observed in these studies, even at high doses and fast infusion rates (up to 30 mg/kg at 10 mg/kg/min), despite multiple morbidities or other antiepileptic drugs. The most serious concern relates to the possibility of acute encephalopathy, sometimes related to hepatic abnormalities or hyperammonemia.

Conclusions The published experience is consistent with VPA being a safe and effective therapeutic option for patients with established SE who have previously failed conventional first-line treatment with benzodiazepines, but high-quality randomized controlled trials are needed to inform clinicians on its comparative effectiveness in SE.
The overall response rate to abrogate status epilepticus (SE) with intravenous (IV) valproate was 70.9% (601 out of 848 patients; 95% confidence interval [CI] 67.8–73.9), with a most commonly used dose between 15 and 45 mg/kg in bolus (6 mg/kg/min) followed by 1–3 mg/kg/h infusion.

The incidence of adverse events was low overall (<10%), mainly dizziness, thrombocytopenia, and mild hypotension, which was independent of infusion rates, and a good cardiovascular and respiratory tolerability even in high doses and fast infusion rates up to 30 mg/kg at 10 mg/kg/min.

Given the low incidence of clinically relevant adverse events, and the potentially serious or even fatal consequences of not abrogating seizure activity rapidly in SE, the ratio of benefit to risk seems clearly in favor of treatment.

Though IV valproate appears to be an effective and safe treatment with good tolerability in SE, there is an urgent need for high-quality randomized controlled trials to inform clinicians on the best treatment in SE.

1 Introduction

Status epilepticus (SE) can be defined as “a condition characterized by an epileptic seizure that is so frequent or so prolonged as to create a fixed and lasting condition” [1]. In light of the seriousness of the condition and the urge to treat as early as possible to prevent refractory SE, the timeframe has been progressively shortened to a pragmatic definition of 5 min ongoing seizures [2]. Indeed, if left untreated, SE is potentially fatal or can lead to irreversible brain damage. Population-based studies [3–8] have estimated an incidence of up to 60 cases per 100,000 per year, with the highest incidence in young children and the elderly [9]. Thus, it represents one of the most common neurological emergencies.

There is general agreement that treatment of SE should follow a staged treatment protocol [10]. Randomized controlled trials show that intravenous lorazepam [11–13] or intramuscular midazolam [14, 15] are the most efficient treatment in early status. Approximately 30–40% of all patients fail to respond to initial treatment with benzodiazepines and need further treatment with intravenous antiepileptic drugs (AEDs). A high proportion of these remain refractory, necessitating the use of anesthetics [12, 16–18]. Intravenous phenytoin or phenobarbital is widely used as treatment for established status. However, these drugs are not efficacious in several epilepsy syndromes and there are tolerability issues associated with their use. Both phenobarbital and phenytoin may cause cardiac arrhythmias, hypotension, and respiratory depression, the latter being aggravated by co-administration with benzodiazepines [17].

Intravenous formulations of other AEDs, including valproate, levetiracetam, and lacosamide have generated considerable interest in their potential use for the treatment of established SE after failure of benzodiazepines [19–22]. The first case reports demonstrating the utility of valproate administered rectally for controlling SE go back to the late 1970s [23–26] and continued to be described throughout the 1980s and 1990s [27] until intravenous valproate was introduced [19, 28].

The fact that SE generally occurs without warning, and the need to treat SE as a medical emergency, means that classical randomized clinical trials corresponding to contemporary regulatory standards are extremely challenging to perform. Thus, there are no class I data to support treatment recommendations on the choice of AED for established and refractory SE. Nonetheless, the published literature contains extensive information on the efficacy and safety of intravenous valproate in the treatment of SE, which has been used as the basis for regulatory approval of this treatment in such selected countries as Norway and Germany.

This article provides a systematic literature review of the current evidence for the efficacy and tolerability of valproate in the treatment of SE.

2 Methods

A comprehensive review of the literature and searches to find unpublished trials was performed to minimize publication bias. The electronic database MEDLINE (January 1966–19 March 2013; accessed by PubMed) was comprehensively searched. The medical subject heading (MeSH) terms ‘valproic acid’ and ‘status epilepticus’, as well as the following free terms were used in multiple search strategies with Boolean operators to find relevant articles published until 19th March 2013: ‘valproate’, ‘valproic acid’, and ‘status epilepticus’.

The following search strategy was applied: (‘valproic acid’ [MeSH] OR valpro* OR valproic acid OR valproate) AND (‘status epilepticus’ [MeSH] OR status epilepticus)).

All resulting titles and abstracts were evaluated, and any relevant article was considered. There were no language restrictions.
All identified studies were cross referenced to identify any reports that may have been missed. The manufacturer of valproate (Sanofi-Aventis) was asked for any reports of further unpublished studies. For the analysis of efficacy, case reports were excluded, since it is not possible to determine response rates from individual cases. For the same reason, studies in which multiple AEDs were evaluated without presentation of results for individual AEDs were also excluded. Studies using intravenous valproate as first-line treatment or after failure of first-line benzodiazepines (lorazepam or diazepam) were considered eligible. For each study, response rates were extracted as the proportion of patients whose seizures resolved after valproate treatment. Seizure resolution was most frequently adopted in the studies as outcome for efficacy. However, cessation of seizure activity, or AED efficacy, was defined differently by different authors in the selected studies; some were based on termination of seizures alone and others based on a lack of recurrence for a certain period of time. Furthermore, in some studies, seizure resolution was based on clinical signs alone and in other studies on the assessment of electrographic seizure activity.

The frequency of adverse events reported in the studies, particularly hypotension and respiratory depression, was used for the analysis of safety; the worldwide pharmacovigilance database of Sanofi-Aventis was also interrogated to identify reported adverse events.

3 Results

3.1 Studies Identified

The search strategy yielded 433 results (425 MEDLINE, seven congress abstracts, one unpublished study). After excluding duplicate publications and case reports, 55 articles were provisionally selected. We excluded 25 studies after reading the full published papers; thus, 30 studies contributed to this review: the earliest was published in 1993 and the most recent in 2012.

Overall, we identified through a comprehensive search in MEDLINE 25 publications in which the efficacy of intravenous valproate in SE had been reported [29–53]. Cross-referencing identified seven additional reports in congress abstracts [54–60]. Three of these were redundant [55, 57, 60] as they corresponded to case series subsequently described in full published papers as part of larger cohorts [35, 40, 45]. Finally, the manufacturer of valproate provided the clinical study report of an unpublished study [61].

Of the 30 unique studies identified, six were randomized controlled trials, none of them blinded, comparing intravenous valproate to phenytoin, diazepam, or phenobarbital [41–43, 46, 52, 53], and four non-randomized controlled studies comparing intravenous valproate to phenytoin or levetiracetam [48–51]. One randomized controlled trial also included patients with acute repetitive seizures not entailing the diagnosis of SE. For this study, information from patients with SE was obtained from a systematic review [62]. Of the uncontrolled studies, eight were prospective observational studies and 12 were retrospective case series.

3.1.1 Randomized Controlled Studies

Three randomized controlled studies compared intravenous valproate with intravenous phenytoin [41, 42, 46], two with intravenous diazepam [43, 52], and one with intravenous phenobarbital [53]. These studies included 361 patients (183 were randomized to receive valproate; Table 1; Fig. 1). The phenobarbital study [53] and one diazepam study [43] included only children; one phenytoin study [46] included only adults, whereas the remaining studies [41, 42, 52] included all age groups. The most frequent SE was generalized convulsive. Valproate was administered most often at an initial bolus dose of 20 or 30 mg/kg (Table 2).

3.1.2 Non-Randomized Controlled Trials

Non-randomized controlled studies were included in the present review. Two studies utilized a prospective design [49, 50], and two were retrospective [48, 51]. These studies included 455 subjects (197 were randomized to valproate; Table 1).

3.1.3 Prospective Open-Label Studies

The eight prospective studies identified are presented in Table 1. Overall, these included 191 patients with SE treated with intravenous valproate (135 adults, 46 children, and ten of unspecified age). These studies all evaluated intravenous valproate administered in monotherapy, usually administered as a bolus (15–40 mg/kg) followed by a maintenance infusion.

3.1.4 Retrospective Case Series

We identified 12 retrospective case series (Table 3). These included 76 adults, 45 children, and 135 subjects of unspecified age with SE. Again, valproate was usually administered as a bolus (15–40 mg/kg) followed by a maintenance infusion.
### 3.2 Seizure Outcome

Response rates are presented in Table 4. These rates varied across studies, between 35 and 100 % (median 74.35 %). The overall response rate in all studies was 70.9 % (601/848; 95 % confidence interval [CI] 67.8–73.9). Outcome in children (81.3 %; 104/128; 95 % CI 74.5–88) was better than in adults (68.5; 207/302; 95 % CI 63.3–73.8). Response rate was lower in controlled non-randomized studies (61.8 %, 114/185; 95 % CI 54.6–66.6) than in randomized controlled studies (75.4 %; 138/183; 95 % CI 69.2–81.6) or retrospective case series (68.2 %; 197/289; 95 % CI 62.8–73.8). There was no difference in response rates in convulsive (69.7 %; 246/353; 95 % CI 64.9–74.5) compared with non-convulsive SE (75 %; 15/20; 95 % CI 56–94), although the comparison is limited by the small number of studies in which outcome was presented according to SE type.

### 3.2.1 Comparative Randomized Studies

Six studies have compared the efficacy of intravenous valproate with that of intravenous phenytoin, diazepam, or phenobarbital. Two studies compared valproate with phenytoin in early SE [43, 46], whereas one study compared valproate with phenytoin in established SE [42].

In the first study [41] comparing the rate of response, defined as seizure cessation at the end of the infusion, it was significantly ($p = 0.046$) higher in the valproate group (66 %; $n = 35$) than in the phenytoin group (42 %; $n = 33$). Non-responders were switched to the other treatment, where 15 of 19 non-responders to phenytoin (79 %) responded to valproate compared with 3 of 12 non-responders to valproate (12 %) who responded to phenytoin ($p = 0.004$). Seizure freedom at 24 h was obtained in 29 patients, irrespective of treatment group or sequence. However, the use of a maintenance AED regimen after the bolus infusion was not reported in this study.

### Table 4 Randomized comparative studies evaluating intravenous valproate monotherapy in the treatment of status epilepticus. Studies are listed in decreasing order of sample size. All studies were carried out as single-center open-label trials, except Malamiri et al., which was conducted in two centers

| References          | N     | Patients                  | Type of SE                  | Dose regimen                                                                 |
|---------------------|-------|---------------------------|----------------------------|------------------------------------------------------------------------------|
| Agarwal et al. [42] | V: 50 | 62 adults/38 children (<18 y), 67 male/33 female | Primary generalized seizures: 14, JME: 2 | V: Initial bolus 20 mg/kg at 40 mg/min, P: Initial bolus 20 mg/kg at up to 50 mg/min |
| Misra et al. [41]   | V: 35 | Adults and children (1–25 y), 41 male/27 female | Convulsive SE (unspecified) | V: Initial bolus 30 mg/kg in 100 ml over 15 min, P: Initial bolus 18 mg/kg in 100 ml infused at 50 mg/min |
| Gilad et al. [46]   | V: 18 | Adults (>18 y), 19 male/7 female | GTC SE | V: Initial bolus 30 mg/kg in 50 ml of saline over 20 min, P: Initial bolus of 18 mg/kg in 100 ml of saline over 20 min |
| Chen et al. [47]    | V: 30 | Children and adults (>15 y), 36 male/30 female | GTC and sGTC SE | V: Initial bolus 30 mg/kg at 6 mg/kg/min followed by continuous infusion at 1–2 mg/kg/h, D: Initial (third) bolus of 0.2 mg/kg at 5 mg/min followed by infusion at 4 mg/h for 3 min and then increased every 3 min by 1 µg/min until seizure control or maximal duration (1 h) reached |
| Mehta et al. [43]   | V: 20 | Children (≤12 y) (mean 3.7), 31 boys/9 girls | GTC SE: 18, sGTC SE; 12, Simple focal SE: 8, Multifocal: 2 | V: Initial bolus 30 mg/kg over 2–5 min; if SE uncontrolled, repeat bolus then infusion at 5 mg/kg/h, D: 10 µg/kg/min initial infusion increased by 10 µg/kg/h every 5 min if SE uncontrolled up to 100 µg/kg |
| Malamiri et al. [53] | V: 30 | Children (>2 y) (median 5, range 3–16), 37 boys/23 girls | Convulsive SE (all subtypes) | V: Initial bolus 20 mg/kg in 20 ml saline at max. 5–6 mg/kg/min over 5–10 min, B: Initial bolus 20 mg/kg at max. 60–100 mg/min |

*phenobarbital, D diazepam, GTC generalized tonic-clonic, JME juvenile myoclonic epilepsy, P phenytoin, SE status epilepticus, sGTC secondary generalized tonic-clonic, V valproate*
In the second study [46], treatment success was defined as clinical seizure cessation after infusion without need for rescue medication within 20 min of the infusion. No statistically significant difference in the rate of treatment success was found among patients treated with valproate (13 of 18; 72.2 %) and phenytoin (seven of nine patients; 77.8 %). Seizure freedom at 24 h was obtained in all patients (100 %) in both groups.

In the study comparing valproate with phenytoin in established SE, treatment success was defined as cessation of all motor and electroencephalography (EEG) seizure activity within 20 min of starting drug infusion and no return of seizure activity in the following 12 h [42]. According to this criterion, 44 patients receiving valproate (88 %) and 42 receiving phenytoin (84 %) experienced treatment success. Success rates were higher in patients in whom SE had been treated within 2 h \( (p < 0.05) \), with only one such patient treated with phenytoin failing to respond.

In the study comparing valproate with diazepam, both in children and in adults, generalized convulsive SE was controlled in 56 % (20 of 36 patients) of the diazepam group and 50 % (15 of 30 patients) in the valproate group [52]. Relapse of SE within 24 h occurred in 25 % (5 of 20 patients) of the diazepam and 20 % (3 of 15 patients) of the valproate group. Both failed to reach statistical significance, suggesting no differences between groups in terms of efficacy.

A recent systematic review assessing the role of valproate in generalized convulsive SE included the above-mentioned studies comparing intravenous valproate with intravenous phenytoin [41, 42, 46] in a meta-analysis [62]. Compared with phenytoin, intravenous valproate had no

---

**Table 2** Non-randomized comparative studies evaluating intravenous valproate monotherapy in the treatment of SE

| References          | N     | Patients                  | Type of SE | Dose regimen                                      |
|---------------------|-------|---------------------------|------------|---------------------------------------------------|
| Tripathi et al. [49]| V: 41, L: 41 | Adults (>14 y), 42 male/40 female | Refractory GTC SE | V: Initial bolus 30 mg/kg at 5 mg/kg/min, L: initial bolus 30 mg/kg at 5 mg/kg/min |
| Tiamkao and Sawanyawisuth [48] | V: 32, P: 37 | Adults (>15 y), No information on gender | GTC SE | V: Initial bolus 15–25 mg/kg with max infusion rate of 50 mg/min, P: Initial bolus 15–20 mg/kg with max infusion rate of 50 mg/min |
| Kalita et al. [50]  | V: 65, P: 52 | 22 children (<12 y), 95 adults, 73 male/44 female | GTC SE: 108, NCSE: 9 | V: Initial bolus 30 mg/kg, P: Initial bolus 20 mg/kg |
| Alvarez et al. [51] | V: 59, P: 70, L: 58 | Adults (>16 y), No information on gender | SE (all subtypes including NCSE) | V: Initial bolus 20 mg/kg with maintenance dosage 1,000–2,500 mg/day, P: Initial bolus 20 mg/kg with maintenance dosage 300–400 mg/day, L: Initial bolus 20 mg/kg with maintenance dosage 1,000–3,000/day |

Studies are listed in decreasing order of sample size

a 12 and 20 patients received intravenous valproate as the first- and second-line therapy, respectively

GTC generalized tonic–clonic, L levetiracetam, NCSE non-convulsive status epilepticus, P phenytoin, SE status epilepticus, V valproate
statistically significant differences in seizure cessation after drug administration (risk ratio [RR] 1.31, 95 % CI 0.93–1.84) and in seizure freedom at 24 h (RR 0.96, 95 % CI 0.88–1.06).

In the study comparing valproate with diazepam in children, SE was successfully controlled in 16/20 patients receiving valproate (80 %) and 17/20 patients receiving diazepam (85 %) [43]. The median time to abrogation of seizure activity was shorter ($p < 0.001$) in the valproate (5 min) than in the diazepam group (17 min). Break-through seizures during the maintenance phase occurred in eight patients in each group.

In the study comparing intravenous valproate with intravenous phenobarbital in children, treatment success was defined as cessation of all convulsive activity within 20 min of anticonvulsant infusion [53]. Seizure termination was significantly higher among patients treated with intravenous loading of valproate (27 of 30 patients; 90 %) than in patients treated with phenobarbital (23 of 30 patients; 77 %) ($p = 0.189$). In the phenobarbital group, a statistically significant higher relapse of SE within 24 h was observed (12 of 23 children) compared with valproate treatment (4 of 27 children).

### 3.2.2 Comparative Non-Randomized Studies

Four studies have compared the efficacy of intravenous valproate with that of intravenous phenytoin or levetiracetam [48–51].

---

**Table 3** Prospective open-label studies evaluating intravenous valproate monotherapy in the treatment of status epilepticus

| References          | N     | Patients                        | Type of SE                  | Dose regimen                                      |
|---------------------|-------|---------------------------------|-----------------------------|---------------------------------------------------|
| Olsen et al. [45]   | 41    | Adults (20–85 y)                | GTC SE: 19                  | Initial bolus 25 mg/kg over 30 min                 |
|                     |       | 18 men/23 women                 | Complex partial SE: 16      | Followed by infusion 100 mg/h for ≥24 h            |
|                     |       |                                 | Unclassifiable: 6           | Median bolus dose 1,800 mg (range 700–2,500 mg)   |
| Überall et al. [33] | 41    | Children (≤16 y)                | GTC SE: 10                  | Initial bolus 20–40 mg/kg over 1–5 min            |
|                     |       | 27 boys/14 girls                | sGTC SE: 9                  | Repeated after 10–15 min if necessary             |
|                     |       |                                 | Absence status: 5           | Then 5 mg/kg/h infusion                           |
|                     |       |                                 | Infantile spasms: 4        |                                                   |
|                     |       |                                 | Neonatal SE: 5              |                                                   |
|                     |       |                                 | EPC: 2                      |                                                   |
|                     |       |                                 | Complex partial SE: 6       |                                                   |
| Giroud et al. [29]  | 23    | Adults (17–80 y)                | GMC SE: 2                   | Initial bolus 15 mg/kg                             |
|                     |       | 13 men/10 women                 | GM SE: 2                    | Followed 30 min later by infusion at 1 mg/kg/h    |
|                     |       |                                 | PM SE: 10                   | Mean total dose: 19.4 mg/kg                        |
|                     |       |                                 | PMC SE: 1                   |                                                   |
|                     |       |                                 | Absence status: 2           |                                                   |
| Czapiński and       | 20    | Adults (16–76)                  | Simple partial SE: 11       | Initial bolus 15 mg/kg                             |
| Terczyński [30]     |       | 11 men/9 women                  | GTC SE: 9                   | Followed 30 min later by infusion at 1 mg/kg/h    |
|                     |       |                                 |                              | for 24 h                                          |
| Ramsay et al. [65]  | 10    | Age and gender not specified    | Not specified               | Bolus infusion 20–30 mg/kg at 0.3–0.5 mg/kg/min   |
|                     |       |                                 |                              | Total dose up to 3,000 mg within 12 min           |
| Leninger and Hofnagel [56] | 6  | Adults (23–70)                  | NCSE                        | 900–3,000 mg/24 h infusion over 2 days            |
| Narayanan and Murthy [44] | 22 (2) | 3 children/19 adults            | NCSE                        | Not specified                                     |
|                     |       | 11 male/11 female               |                              |                                                   |
|                     |       | (2 adult women)                 |                              |                                                   |
| Chen et al. [47]    | 48    | 5 children (<15 y) and          | GTC SE: 30                  | Initial bolus of 15 mg/kg over 5 min (repeated    |
|                     |       | 43 adults (>15 y)               | sGTC SE: 14                 | 10–15 min if necessary), followed by continuous   |
|                     |       | 19 male/29 female               | TSE: 4                       | infusion at 30 mg/kg, infused at an hourly rate   |

---

* The figures in brackets refer to subjects receiving intravenous valproate monotherapy in studies where more than one AED was studied.

EPC epilepsy partialis continua, GMC generalized myoclonic, GTC generalized tonic–clonic, NCSE non-convulsive status epilepticus, PM partial motor, PMC partial myoclonic, SE status epilepticus, sGTC secondary generalized tonic–clonic, TSE tonic status epilepticus
One prospective study compared intravenous valproate with intravenous levetiracetam in adults with refractory SE at a tertiary center in India [49]. Refractory SE was defined as seizures lasting for more than 1 h, and patients had to have already received intravenous lorazepam and phenytoin. Clinical seizure cessation after infusion was obtained by 26 of 41 patients in the valproate group (68.3 %) and 28 of 41 patients in the levetiracetam group (73.2 %), although the difference was not statistically significant. Seizure control was not reached by 13 (31.7 %) patients in the valproate group and 11 (26.8 %) in the levetiracetam group (difference not statistically significant), and patients required intubation and administration of propofol or midazolam infusion.

One retrospective study was conducted in adults with convulsive SE who were treated with intravenous valproate as first- or second-line AED [48]; 12 (24 %) and 37 (76 %) patients were treated with intravenous valproate and phenytoin as first-line treatment, respectively. Treatment success was defined as the cessation of seizures by either clinical or EEG evidence. SE ceased in 9 of 12 patients (75 %) with intravenous valproate and 17 of 37 patients (46 %) with intravenous phenytoin as first-line treatment (difference not statistically significant), whereas it ceased

### Table 4

| References                  | N     | Patients                          | Type of SE | Dose regimen                                                                 |
|-----------------------------|-------|-----------------------------------|------------|-----------------------------------------------------------------------------|
| Limdi et al. [39]           | 63    | Age range not specified           | Not specified | Bolus 10–78 mg/kg until serum levels reach 278 mg/l                         |
| Czapiński [54]              | 120   | Age and gender not specified      | Not specified | Initial bolus 15 mg/kg                                                      |
| Peters and Pohlmann-Eden [40]| 35    | Adults (18–85 y)                  | GTC SE: 6   | Bolus infusion 4–16 mg/kg for 5–10 min                                     |
|                            |       | 18 men/17 women                   | Simple partial: 12 | Followed by infusion of 0.5–4 mg/kg/h for 4 h to 6 days                  |
|                            |       |                                   | Complex partial: 14 |                                                                           |
|                            |       |                                   | Absence status: 3 |                                                                           |
| Naritoku [34]               | 32    | Mean age 68.5 y                   | GTC SE: 12  | Bolus infusion 25 mg/kg                                                     |
|                            |       | Gender unspecified                | Other: 20   | Mean serum concentration 80.1 mg/l                                         |
| Rosenow and Knake [35]      | 27    | Adults (22–94 y)                  | sGTC SE: 11 | Bolus infusion 300–800 mg (mean 1,000 mg)                                  |
|                            |       | Gender unspecified                | Partial SE: 7 | Followed by infusion of 1,200–1,800 mg/24 h                               |
|                            |       |                                   | Absence status: 2 |                                                                           |
| Campistol et al. [31]       | 19    | Children (<7 y)                   | IG SE: 4    | Initial bolus 20 mg/kg                                                     |
|                            |       | 10 boys/9 girls                   | SP SE: 2    | Followed by infusion at 1 mg/kg/h                                          |
|                            |       |                                   | Other secondary: 17 |                                                                           |
| Yu et al. [37]              | 40    | Children (<19 y)                  | Not specified | Bolus infusion 25 mg/kg at 2.8 mg/kg/min                                   |
|                            |       | (18)a                             |             |                                                                           |
| Katragadda et al. [32]      | 12    | 1 child, 11 adults                | Partial NCSE: 9 | Not specified                                                               |
|                            |       | Gender unspecified                | Absence status: 3 |                                                                           |
| Price [61]                  | 11    | 6 children (6–17 y)               | Not specified | Not standardized                                                            |
|                            |       | 5 adults (26–72 y)                |             |                                                                           |
|                            |       | 7 male/4 female                   |             |                                                                           |
| Jha et al. [36]             | 11    | 2 children (7, 15 y)              | GTC SE: 1   | Bolus infusion 20 mg/kg at 20 mg/min                                        |
|                            |       | 9 adults (24–60 y)                | EPC: 5      | Repeated as necessary                                                       |
|                            |       | 7 male/4 female                   | Myoclonic SE: 4 |                                                                           |
|                            |       |                                   | NCSE: 1     |                                                                           |
| Patel and Jha [38]          | 10    | Adults (18–60 y)                  | Post-anoxic myoclonic SE | Bolus infusion 20 mg/kg at 20 mg/min                                      |
|                            |       | 3 men/7 women                     |             | Followed by 10 mg/kg every 6 h for 24 h                                    |
| Short [59]                  | 22    | All ages (2–75 y)                 | Not specified | Mean initial dose: 1.020 ± 946 mg                                           |
|                            | (7)a  | Mean age 40 y                      |             | Mean total dose: 19,017 ± 30,196 mg                                        |
|                            |       |                                   |             | Mean infusion rate: 21 ± 13 mg/min                                          |

* The figures in brackets indicate the number of subjects receiving intravenous valproate monotherapy

EPC epilepsy partialis continua, GTC generalized tonic–clonic, IG idiopathic generalized, NCSE non-convulsive status epilepticus, SE status epilepticus, sGCT secondary generalized tonic–clonic, SP simple partial
in 7 of 20 (35%) patients who received second-line valproate.

Kalita et al. [50] conducted a prospective study in children and adults with convulsive and non-convulsive SE, comparing first-line intravenous valproate with first-line intravenous phenytoin. A total of 65 patients received valproate and 52 received phenytoin as a first-line AED, which resulted in control of SE in 56% of patients with valproate and 44% of patients with phenytoin. Crossing over of the treatment in uncontrolled patients resulted in seizure cessation in 41 additional patients, whereas 35 (30%) remained refractory to both valproate and phenytoin. Within 24 h, seizures recurred in six patients whose SE initially responded to the first or second AED (no further information on valproate or phenytoin was available in the published article).

A retrospective study compared intravenous valproate with phenytoin or levetiracetam as second-line treatment in adults [51]. The primary outcome was the failure of the second-line AED, defined as the need to introduce a further compound to control SE; 15 of 59 patients in the valproate group (25.4%) failed to control seizures, compared with 29 of 70 patients in the phenytoin group (41.4%) and 28 of 58 patients in the levetiracetam group (48.3%).

### 3.2.3 Status Epilepticus (SE) Subtypes

#### 3.2.3.1 Generalized Tonic–Clonic SE

The largest group of patients for whom seizure outcome has been reported by seizure type corresponds to patients presenting with generalized tonic-clonic SE. Specific outcome was reported in ten studies [29, 30, 33, 34, 36, 40, 45, 47, 49, 52], including a total of 166 patients. Most subjects (119/166) responded to treatment, yielding an overall response rate of 71.7% (95% CI 68.3–75.1).

#### 3.2.3.2 Focal SE

The other type of SE in which intravenous valproate has been most frequently evaluated is simple or complex focal SE. Overall, data have been reported for 107 patients, included in nine studies [29–31, 33, 34, 36, 45, 47, 52], including a total of 166 patients. Most subjects (83/107) responded to treatment, with an overall response rate of 77.6% (95% CI 75.3–79.9).

#### 3.2.3.3 Absence Status

Information on the effectiveness of monotherapy with intravenous valproate in absence status is limited. Such patients have been reported in six studies [29, 32, 33, 36, 44, 57]. The number of subjects in these studies was low (16 overall, ranging from one to five patients per study). In all studies except one [57], including three patients in whom absence status was described as atypical, SE was rapidly abrogated by valproate treatment in the majority of cases (12/16 cases). The overall response rate in absence status was 75.0% (95% CI 53.8–96.2). In one study, two patients with absence status received valproate as first-line therapy rather than after failure of intravenous benzodiazepines [44]. Both of these patients responded to treatment.

#### 3.2.3.4 Other Presentations of SE

Three patients with myoclonic SE were studied by Giroud et al. [29] and four such patients by Jha et al. [36]. One patient in each study failed to respond. The overall success rate was thus 71%. Patel and Jha [38] reported ten patients with post-anoxic myoclonic SE occurring after surgery. SE was abrogated successfully in six of these patients (60%) with intravenous valproate given at a dose of 30 (four patients) or 40 (two patients) mg/kg within 2–10 h. In addition to these patients, two cases of successful treatment of myoclonic SE have been reported by Sheth and Gidal [63]. Überall et al. [33] reported two cases of status associated with infantile spasms; both responded successfully to intravenous valproate therapy.

### 3.2.4 Seizure Outcome and Order of Valproate Administration

Two randomized [41, 46] and one non-randomized [50] controlled trials used valproate as first-drug antiepileptic treatment instead of benzodiazepines. Four randomized [42, 43, 52, 53] and three non-randomized [48, 49, 51] controlled trials used valproate after failure of first-line benzodiazepines (lorazepam or diazepam).

Among studies using valproate as second-line drug, SE was controlled in 50–90% of patients allocated to valproate in randomized controlled studies, and in 56% of patients treated with valproate in the non-randomized controlled trial. Among studies using valproate as first-line drug, SE was controlled in 66–72.2% of patients allocated to valproate in randomized controlled studies, and in 68.3–75% of patients treated with valproate in non-randomized controlled trials.

### 3.3 Safety

Information on the safety of intravenous valproate derives from a limited number of dedicated safety studies, adverse event reporting in the efficacy studies described above, individual case reports, and pharmacovigilance reporting.
3.3.1 Dedicated Safety Studies

A number of dedicated studies have investigated the safety of intravenous valproate in patients with epilepsy during the clinical development of this formulation. Not all of these studies concern patients with SE, but the data obtained are nonetheless pertinent to the risk–benefit assessment of intravenous valproate in SE.

The largest of these studies included 318 patients, both children and adults, with epilepsy and hospitalized for seizure-related reasons [64]. The initial dose was 15 mg/kg/day in four divided doses every 6 h. Subsequent doses were adjusted at the discretion of participating investigators as a function of serum valproate concentrations. The median dose of valproate administered was 375 mg infused over 1 h. The median number of doses was four, given over 2 days. Transient adverse events were reported in 54 patients (17.5 %), most frequently headache, injection-site reactions, nausea, somnolence, vomiting, dizziness, and taste perversion. None were reported in more than seven patients (2.3 %). No changes in hematomal parameters, blood chemistry, or vital signs were observed.

A second large study compared infusion of valproate at either 1.5 or 3 mg/kg/min in 112 hospitalized children or adults with epilepsy [65]. The maximum dose per infusion permitted was 15 mg/kg, and the maximum number of infusions per 24 h period was four. The primary outcome was changes in blood pressure during and after the first valproate infusion. Although no change in mean blood pressure was observed in the sample as a whole, two subjects infused at a rate of 3 mg/kg/min presented transient hypotension. The most common adverse events reported were somnolence, paresthesia, dizziness, and nausea. None of the patients had any alteration of consciousness. A possibly treatment-related case of encephalopathy was reported as a serious adverse event in a patient receiving valproate at an infusion rate of 3 mg/kg/min (peak serum valproate concentration of 123 μg/ml), which resolved upon discontinuation of valproate. No clinically significant abnormalities in blood chemistry or hematology were noted.

A number of other smaller safety studies [66–69] have reported adverse event profiles similar to these two large studies. In addition, one case of asymptomatic hyperammonemia has been described [66]. More recently, a prospective study on 40 patients receiving an intravenous loading dose of 20 mg or 30 mg at 6 mg or 10 mg/kg/min of valproate found asymptomatic hyperammonemia in 30 of 40 patients 1 h after the infusion, decreasing to 66 % at 24 h after infusion [70]. None of the patients had any alteration of consciousness or increase of transaminases.

Concerning more rapid injection schedules, one study [68] compared blood pressure changes and adverse events between 36 patients infused at a rate of 3 mg/kg/min up to a maximum dose of 15 mg/kg, 24 patients infused at 3 mg/kg/min up to 30 mg/kg, and six patients infused at 6 mg/kg/min up to 15 mg/kg. No increase in the incidence of adverse events was seen with the higher dose or faster infusion rate, and no changes in blood pressure were observed. Subsequently, infusion rates of up to 11 mg/kg/min have been reported in pediatric patients, with no untoward safety issue being identified [71].

Since hypotension is a concern with other intravenous AED treatments for SE, such as phenytoin, a retrospective analysis has been performed of the hemodynamic effects of intravenous valproate used to control SE in 13 patients with antecedents of hypotension or cardiovascular instability [72]; 12 of these patients were elderly (>64 years). The mean loading dose of intravenous valproate was 25.1 ± 5.0 mg/kg infused at a rate of 36.6 ± 25.1 mg/min, which produced serum valproate concentrations after completion of the infusion of 78.7 ± 35.8 mg/l. All except one patient received vasopressors (dopamine or dobutamine) before the valproate infusion began. No significant changes in systolic or diastolic blood pressure were observed during or after valproate infusion, and increases in vasopressor dose were not required. No other cardiovascular adverse effects or changes in cardiac rhythm were observed.

An open-label, prospective trial evaluated the safety of rapid intravenous loading of undiluted valproate (20 or 30 mg/kg/min at rates of 6 or 10 mg/kg/min) in 40 patients with epilepsy [69]. Rapid administration of valproate was well tolerated, with no significant changes in heart rate and mean arterial pressure by dose group (20 mg/kg, 30 mg/kg) across time (measurements at 20, 30, 45, 60, and 240 min after administration). No patient exhibited alteration of consciousness at 30–60 min after dose administration compared with baseline, although three patients (7.5 %) complained of sedation and one of nausea. There were no disturbances in cardiac conduction or arrhythmias as indicated by normal electrocardiogram (ECG) in all patients at all time points. A total of 30 patients (81.5 %) complained of local irritation (pain/burning or paresthesias) lasting less than 3 min, with no indication of redness, irritation, or phlebitis. No significant changes in platelets or hepatic parameters were observed.

Although this study was not conducted in patients with SE, rapid administration of undiluted valproate proved safe and well tolerated, supporting its use in emergent situations.

The risk of local injection-site reactions with intravenous valproate was explored specifically in a retrospective chart review of two double-blind randomized clinical trials evaluating the use of valproate or phenytoin to prevent post-traumatic seizures in 775 patients with traumatic brain
disparate nature of adverse event reporting between studies in Table 6. Interpretation of these studies is limited by the and retrospective case series discussed above are presented. Adverse events reported in the other prospective studies 3.3.4 Uncontrolled Studies and Case Series

The four comparative not-randomized studies included 197 patients treated with valproate. The incidence of hypoten-
sion and respiratory depression was reported in only one study, showing no difference between the drugs (0 %) [49]. Conversely, the incidence of hypotension was equal to that of intravenous phenobarbital (0 %), whereas the incidence of respiratory depression was lower for valproate than that reported for intravenous phenobarbital (3.3 %). On the other hand, the incidence of liver abnormalities was higher than that reported for intravenous phenytoin (2.2 %). Given the low patient numbers, none of the differences reported in the individual studies were statistically significant.

A recent systematic review assessing the role of valproate in generalized convulsive SE included the studies comparing intravenous valproate with intravenous phenytoin [41, 42, 46] in a meta-analysis [62]. Compared with phenytoin, intravenous valproate had a statistically lower risk of adverse effects (considered as a whole) (RR 0.31, 95 % CI 0.12–0.85).

3.3.3 Comparative Not-Randomized Studies

The four comparative not-randomized studies included 197 patients treated with valproate. The incidence of hypoten-
sion and respiratory depression was reported in only one study, showing no difference between the drugs (0 %) [49].

3.3.4 Uncontrolled Studies and Case Series

Adverse events reported in the other prospective studies and retrospective case series discussed above are presented in Table 6. Interpretation of these studies is limited by the disparate nature of adverse event reporting between studies and incomplete ascertainment. Nevertheless, the nature and frequency of the adverse events described are essentially similar to what was observed in the dedicated safety studies. The most frequently reported side effects were nausea/vomiting, dizziness, and sedation (Tables 7 and 8).

3.3.5 Case Reports

A number of case reports have appeared in the literature describing idiosyncratic adverse reactions to intravenous valproate in patients with SE. Several of these have described cases of encephalopathy. For example, Rossetti and Bromfield [76] have described two patients developing acute encephalopathy within 48 h of receiving intravenous valproate for the treatment of SE. Serum valproate concentrations were in the therapeutic range. In these cases, encephalopathy was associated with hyperammonemia twofold higher than normal. Symptoms resolved after reduction of the valproate dose. Embacher et al. [77] described a woman who developed symptoms of encephalo-
pathy within 24 h of receiving intravenous valproate. Again, serum valproate levels were not markedly elevated (29 µg/ml), and serum ammonium was within the normal range. The patient recovered completely within 48 h of discontinuation of valproate. Reversible symptoms of encephalopathy, including confusion or lethargy, were observed in three adult patients with absence SE treated with intravenous valproate and who were on maintenance therapy with lamotrigine [78]. In these patients, the authors related the symptoms to elevated serum levels of lamoti-
gine due to the well characterized pharmacokinetic inter-
action between valproate and lamotrigine, whereby valproate inhibits hepatic glucuronidation of lamotrigine.

In addition to these reports of encephalopathy, a case of significant hypotension following intravenous valproate infusion was described in an 11-year-old girl presenting febrile SE following varicella infection and receiving valproate at a dose of 30 mg/kg over 1 h [79]. This patient had previously received 10 mg of diazepam and then 1.6 mg of lorazepam, shortly before infusion of valproate was initiated in an attempt to control recurrent seizure activity. The contribution of valproate to the onset of hypotension is consequently difficult to determine.

Intravenous administration of valproate can be associated with acute pancreatitis [106] and with hepatic failure.
A case of acute pancreatitis following intravenous valproate administration has been reported, as well as a case of fulminant hepatic failure associated with hemorrhagic shock leading to death in 9-year-old patient with cerebellar syndrome and moderate mental retardation receiving intravenous valproate for the treatment of SE [80].

### Table 5 Seizure outcome in patients receiving intravenous valproate monotherapy for the treatment of status epilepticus

| Study                          | Age group | SE type | Definition of ‘responders’ | Responders/ N<sup>a</sup> | % (95 % CI) |
|-------------------------------|-----------|---------|----------------------------|--------------------------|-------------|
| **Comparative randomized studies** |           |         |                            |                          |             |
| Agarwal et al. [42]           | Mixed     | CSE     | Clinical or EEG seizure cessation within 20 min of infusion | 44/50                    | 88.0 (79–97) |
| Misra et al. [41]             | Mixed     | CSE     | Clinical seizure cessation after infusion | 23/35                    | 65.7 (50–81.4) |
| Gilad et al. [46]             | Adults    | CSE     | Clinical seizure cessation within 20 min of infusion | 13/18                    | 72.2 (51.5–92.9) |
| Chen et al. [47]              | Mixed     | CSE     | Clinical seizure cessation after infusion | 15/30                    | 50.0 (32.1–67.9) |
| Mehta et al. [43]             | Children  | CSE     | Clinical seizure cessation after infusion | 16/20                    | 80.0 (62.5–97.5) |
| Malamiri et al. [53]          | Children  | CSE     | Clinical seizure cessation after infusion within 20 min of infusion | 27/30                    | 90.0 (79.3–100) |
| **Comparative non-randomized studies** |           |         |                            |                          |             |
| Tripathi et al. [49]          | Adults    | CSE     | Clinical seizure cessation after infusion | 26/41                    | 68.3 (48.7–78.2) |
| Tiamkao and Sawanyawisuth [48] | Adults    | CSE     | Clinical seizure cessation within 30 min of infusion | 9/12<sup>b</sup>         | 75 (50.5–99.5) |
| Kalita et al. [50]            | Mixed     | Mixed   | Clinical seizure cessation after infusion | 37/65                    | 56.9 (44.9–69) |
| Alvarez et al. [51]           | Adults    | Mixed   | No additional AEDs needed for ≥48 h after clinical and EEG seizure cessation | 44/59                    | 74.6 (63.5–85.7) |
| **Prospective studies**        |           |         |                            |                          |             |
| Olsen et al. [45]             | Adults    | Mixed   | Clinical seizure cessation after infusion | 31/41                    | 75.6 (62.5–88.8) |
| Überall et al. [33]           | Children  | Mixed   | Clinical seizure cessation after infusion | 32/41                    | 78.0 (65.4–90.7) |
| Giraud et al. [29]            | Adults    | Mixed   | Clinical seizure cessation within 20 min of infusion | 19/23                    | 82.6 (67.1–98.1) |
| Czapinski and Terczyński [30] | Adults    | CSE     | Clinical seizure cessation within 30 min of infusion | 16/20                    | 80.0 (62.5–97.5) |
| Ramsay et al. [65]            | NR        | NR      | NR                         | 6/10                     | 60.0 (26.6–90.4) |
| Leninger and Hofnagel [56]    | Adults    | NCSE    | Clinical seizure cessation after infusion | 4/6                      | 66.7 (28.9–104.4) |
| Narayanan and Murthy [44]     | Adults    | NCSE    | Clinical seizure cessation after infusion | 2/2                      | 100         |
| Chen et al. [47]              | Mixed     | CSE     | Clinical seizure cessation within 1 h of the infusion | 42/48                    | 87.5 (78.1–96.9) |
| **Retrospective case series**  |           |         |                            |                          |             |
| Limdi et al. [39]             | NR        | NR      | No additional AEDs needed for ≥12 h after clinical and/or EEG seizure cessation | 40/63                    | 63.3 (51.6–75.4) |
| Czapinski [54]                | NR        | NR      | Clinical seizure cessation within 30 min of infusion | 33/40                    | 82.5 (70.7–94.3) |
| Peters and Pohlmann-Eden [40] | Adults    | Mixed   | Clinical seizure cessation within 15 min of infusion | 27/35                    | 77.1 (63.2–91.1) |
| Naritoku [34]                 | NR        | CSE     | Clinical seizure cessation after infusion | 16/32                    | 50.0 (32.7–67.3) |
| Rosenow and Knake [35]        | Adults    | Mixed   | NR                         | 12/27                    | 44.4 (25.7–63.2) |
| Campistol et al. [31]         | Children  | CSE     | Clinical seizure cessation after infusion | 11/19                    | 57.9 (35.7–80.1) |
| Yu et al. [37]                | Children  | Mixed   | Clinical seizure cessation within 20 min of infusion | 18/18                    | 100         |
| Katragadda et al. [32]        | Mixed     | NCSE    | NR                         | 9/12                     | 75.0 (50.5–99.5) |
| Price [61]                    | Mixed     | NR      | NR                         | 10/15                    | 66.7 (42.8–90.5) |
| Jha et al. [36]               | Mixed     | Mixed   | Clinical seizure cessation within 24–48 h of infusion | 10/11                    | 90.9 (73.9–107.3) |
| Patel and Jha [38]            | Adults    | CSE     | Clinical seizure cessation after infusion | 6/10                     | 60.0 (29.6–90.4) |
| Short [59]                    | Mixed     | NR      | NR                         | 5/7                      | 71.4 (38–104.9) |

<sup>a</sup> Number of subjects receiving intravenous valproate monotherapy

<sup>b</sup> 12 and 20 patients received intravenous valproate as the first- and second-line therapy, respectively

AED anti-epileptic drug, CI confidence interval, CSE convulsive status epilepticus, EEG electroencephalography, NCSE non-convulsive status epilepticus, NR not reported, SE status epilepticus
months after starting valproate treatment (initially as polytherapy up to 600 mg/day and later as monotherapy up to 1,200 mg/day), the child had nausea and vomiting, with subsequent increasing sleepiness and reduced vigilance. Laboratory exams revealed severe liver failure. Post-mortem examinations showed a microvesicular hepatic steatosis with centro- and mediozonal necrosis, hemoperitoneum, retroperitoneal bleeding, and hemorrhage involving pancreas, adrenal glands, and small bowel. The authors did not rule out the presence of underlying metabolic disorders (organic acidemias, mitochondrial disorders, Alper’s disease).

3.3.6 Pharmacovigilance Data

As of 31 January 2006, a total of 517 medically confirmed adverse drug reactions in 224 patients receiving intravenous valproate had been reported in the worldwide Sanofi-Aventis post-marketing pharmacovigilance database since 1994 [81]. Given the estimated exposure to intravenous valproate over the period (>1 million units prescribed per year worldwide), the reporting rate for adverse events was less than one case per 100,000 administrations. It should be noted that the indication for prescription was not necessarily SE in all these cases, and in many cases the indication was not reported. SE was explicitly reported as the reason for prescription in around one-quarter of these cases. Children, again in all indications, accounted for 21% of the reported events. The most frequently reported adverse drug reactions (between ten and 50 reports each) were hyperammonemia, coma, encephalopathy, metabolic encephalopathy, thrombocytopenia, confusional state, pancreatitis, hepatic failure, somnolence, and EEG abnormalities. Reporting of these events did not necessarily imply that a causal relationship to treatment had been identified. No relevant differences in the distribution of adverse drug reactions were noted between children and adults or between patients known to have received treatment for SE and the others.

4 Discussion

The cumulative literature describes the experiences of over 800 patients with various forms of SE treated with intravenous valproate. The overall response rate to abrogate SE
was 70.9% (95% CI 67.8 to 73.9). This compares favorably to response rates reported in the Veterans Affairs SE Cooperative Study [12], which ranged from 43.6% for phenytoin to 64.9% for lorazepam in early SE, and also to the overall response rates of published literature on intravenous levetiracetam, which is around 70% [19, 20, 82], and lacosamide, which is 56% in recent series [21, 22, 83]. Response rates to intravenous valproate were better in children than in adults and did not differ between the SE types. In addition, absence seizures, which can be aggravated by phenytoin, responded well to intravenous valproate. The most commonly reported effective doses were between 15 and 45 mg/kg in bolus (6 mg/kg/min) followed by 1–3 mg/kg/h infusion, although in the literature higher infusion rates following initial bolus (up to 5 mg/kg/h) have been reported [33]. The response rates were even higher in the randomized controlled trials than in the non-randomized trials and retrospective as well as prospective open series. This finding is not easy to explain, since usually non-randomized trials tend to overestimate the treatment

| Table 7 | Adverse event reporting in four comparative non-randomized studies of valproate in status epilepticus |
|---------|--------------------------------------------------------------------------------------------------|
| Study | Adverse event | Patient numbers in the VPA arm |
| Tripathi et al. [49] | Hypotension | 0/41 |
| | Respiratory depression | 0/41 |
| | Liver dysfunction | 0/41 |
| | Thrombocytopenia | 0/41 |
| Tiamkao and Sawanyawisuth [48] | Adverse effects not reported | |
| Kalita et al. [50] | Adverse effects not reported | |
| Alvarez et al. [51] | Adverse effects not reported | |

| Table 8 | Adverse event reporting in other clinical studies on valproate in status epilepticus |
|---------|----------------------------------------------------------------------------------|
| Study | N | Main safety findings |
| Campistol et al. [31] | 19 | No evidence of important side effects; hyperammonemia, somnolence (two subjects each); thrombocytopenia/lymphopenia (one subject); no hypotension |
| Czapiński and Terczyński [30] | 20 | No adverse events in ten subjects; nausea, injection site pain, abdominal pain (two subjects each); dizziness, taste perversion, somnolence, tremor (one subject each) |
| Czapiński [54] | 40 | No safety data reported |
| Giroud et al. [29] | 23 | Moderate, transient decrease in heart rate and blood pressure; no respiratory changes; no local injection reactions |
| Jha et al. [36] | 11 | No adverse events reported; no respiratory depression or hypotension |
| Katragadda et al. [32] | 12 | Thrombocytopenia in three subjects |
| Leninger and Hofnagel [56] | 6 | No safety data reported |
| Limdi et al. [39] | 63 | Hypotension in three subjects; no injection-site reactions |
| Narayan and Murthy [44] | 2 | Adverse events not reported by treatment group |
| Naritoku [34] | 10 | One case of hyperammonemia; no hypotension |
| Olsen et al. [45] | 41 | One case of moderate hypotension; no other side effects observed |
| Patel and Jha [38] | 10 | No adverse events reported |
| Peters and Pohllmann-Eden [40] | 35 | No severe side effects; mild side effects in seven subjects (dizziness, skin reaction, nausea, fatigue, tremor); no hypotension |
| Price et al. [61] | 11 | One case of thrombocytopenia |
| Ramsay et al. [65] | 10 | No cardiovascular, hematological, or subjective side effects |
| Rosenow and Knake [35] | 27 | No adverse events reported |
| Short [59] | 7 | Hyperammonemia in one subject; sedation and hypotension in two subjects |
| Überral et al. [33] | 41 | No drug-related systemic or local side effects. No biological changes |
| Yu et al. [37] | 18 | No significant changes in heart rate or blood pressure; one case of transient tremor |
| Chen et al. [47] | 48 | No evidence for valproate-related systemic or local side effects |
| Tiamkao and Sawanyawisuth [48] | 32 | Adverse effects not systematically reported |
effect [84]. Two other facts may have contributed to this: in a recent meta-epidemiological study on 139 meta-analyses, trials from less developed countries showed more favorable treatment effects than those in developed countries [85]. Three of the six randomized studies using valproate for SE came from India, one from China, and one from Iran, the latter having the highest response rates (90%). In addition, the etiology, which is recognized as an important predictor of outcome [86, 87], is different from that of the more developed countries, with some of the causes more likely to be easy to control [88–91].

A recent systematic review compared the relative efficacy of five AEDs (valproate, lacosamide, levetiracetam, phenobarbital, phenytoin) in treatment of benzodiazepine-resistant convulsive SE [107]. A dichotomous outcome analysis of a single group estimate was performed for each AED with regards to cessation of seizure activity. The efficacy of valproate was higher (75.7%; 95% CI 63.7–84.8) than that of other AEDs (lacosamide: analysis not performed due to insufficient data; levetiracetam: 68.5%, 95% CI 56.2–78.7; phenobarbital 73.6%, 95% CI 58.3–84.8; phenytoin 50.2%, 95% CI 34.2–66.1). Considered overall, cumulative data from the literature are therefore consistent with valproate being a safe and effective therapeutic option for patients with established SE who have previously failed conventional first-line treatment with benzodiazepines. However, it is important to consider that the methodological heterogeneity of the source literature makes the cumulative response rate reported in our review and previous systematic reviews a relatively imprecise result. Limiting the methodological heterogeneity across studies will be of utmost importance in further research in the treatment of SE: investigators should adopt uniform definitions of SE and its different stages, provide individual patient data, and report their results clearly and explicitly [62].

Studies of the safety of intravenous valproate administration in patients with SE showed a low incidence of adverse events overall (<10%) mainly dizziness, thrombocytopenia, and mild hypotension), which was independent of infusion rates [65, 67, 69, 92]. There were no unexpected side effects compared with the known safety profile of valproate in other indications using oral administration. The low overall incidence of adverse events following infusion, especially the good cardiovascular and respiratory tolerability even in high doses and fast infusion rates up to 30 mg/kg at 10 mg/kg/min [69], of intravenous valproate observed in these studies is all the more noteworthy in that the patients often had multiple morbidities and in some cases had recently received, or were still receiving, other AEDs.

The most serious concern relates to the possibility of acute encephalopathy, sometimes related to hepatic abnormalities or hyperammonemia. This idiosyncratic effect may occur when serum valproate concentrations are in the normal therapeutic range (50–110 µg/ml). However, the number of reported cases is relatively low, and most seem reversible on reduction of the dose of valproate or interruption of treatment. In any case, continued or regular periodic monitoring of the EEG during the stabilization period is desirable for all patients with SE [93], and this can be exploited to detect possible encephalopathy at an early stage. Furthermore, clinicians should monitor lipase, amylase (risk of pancreatitis), ammonium, and transaminase levels. Given the potentially serious or even fatal consequences of not abrogating seizure activity rapidly in SE, the ratio of benefit to risk seems clearly in favor of treatment. Pre-treatment with barbiturates, topiramate, or combinations of both may increase the risk of acute encephalopathy [94–98]. The mechanisms leading to acute encephalopathy are not well understood, but hitherto unrecognized mitochondrial dysfunction may play a crucial role [77, 99]. Thus, valproate should be used with caution in unexplained SE in children.

Intravenous valproate has several other potential advantages for use as a treatment for established SE. Unlike phenytoin and phenobarbital, it does not require organic solvents for dissolution, minimizing the risk of injection-site reactions such as ‘purple glove’. Thus, valproate can be injected at a physiological pH without incompatibility with other commonly used intravenous solutions. The pharmacokinetics of valproate is well characterized [100], and the transition from intravenous to oral therapy can be made smoothly once SE has been controlled and the patient returns to the community [101]. Finally, valproate is a broad-spectrum AED that can be used effectively in virtually all types of epilepsy, and safely in patients whose seizure type is poorly characterized [101, 102]. As such, it would potentially be of particular interest in, for example, absence status, where phenytoin is contraindicated.

Acute treatment of SE is responsible for a high proportion of hospital costs associated with epilepsy. A pharmacoeconomic study conducted in Germany (population 82 million) evaluated that SE causes hospital costs of more than €83 million each year, around one-quarter of the total of epilepsy-related inpatient treatment costs (€342 million); these costs far exceed those for a newly established diagnosis of epilepsy (€49 million) [108]. Although to date no single study has performed a formal assessment of intravenous valproate treatment versus hospital admission and stay, it is reasonable to hypothesize that prompt seizure control may result in lower economic burden to the healthcare system. However, comparative studies are required to determine which AED has the more favorable efficacy/safety/cost profile in the treatment of SE.
5 Conclusions

Intravenous valproate appears to be an effective and safe therapeutic option for patients with established SE who have previously failed conventional first-line treatment with benzodiazepines. However, to inform clinical decision making appropriately, a randomized controlled trial comparing the available treatment options in established SE is needed. Starting from the 2nd London Innsbruck Colloquium of Status Epilepticus [103], a trial protocol has been presented and subsequently developed by a group of researchers from the USA and Europe [104, 105]. Once the tribulations of funding this study are overcome, results can be expected in a few years from now.

Conflict of interest No funding was received related to the preparation of this article.

Eugen Trinka has acted as a paid consultant to Eisai, Ever Neuropharma, Biogen Idec, Medtronsics, Bial, and UCB and has received speakers’ honoraria from Bial, Eisai, GL Pharma, GlaxoSmithKline, Boehringer, Viropharma, Actavis, and UCB Pharma in the past 3 years.

Eugen Trinka has received research funding from UCB Pharma, Biogen-Idec, Red Bull, Merck, the EU, FWF Österreichischer Fond zur Wissenschaftsförderung, and Bundesministerium für Wissenschaft und Forschung. Eugen Trinka is also one of the investigators planning ESETT (Established Status Epilepticus Treatment Trial).

Julia Höfler has received speakers’ honoraria from UCB Pharma and travel support from Eisai and GL Pharma.

Alexander Zerbs has no conflict of interest to declare.

Francesco Brigo received speaker’s honoraria from UCB Pharma.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Gastaut H. Clinical and electroencephalographical classification of epileptic seizures. Epilepsia. 1970;11:102–13.
2. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40:120–2.
3. Coe tyaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology. 2000;55:693–7.
4. Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42:714–8.
5. Vignatelli L, Rinaldi R, Galeotti M, de Carolis P, D’Alessandro R. Epidemiology of status epilepticus in a rural area of northern Italy: a 2-year population-based study. Eur J Neurol. 2005;12:897–902.
6. Govoni V, Fallica E, Monetti VC, Guerzoni F, Faggioni R, Casetta I, et al. Incidence of status epilepticus in southern Europe: a population study in the health district of Ferrara, Italy. Eur Neurol. 2008;59:120–6.
7. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995;12:316–25.
8. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology. 1998;50:735–41.
9. Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia. 2007;48(Suppl 8):S82–4.
10. Shorvon S, Baulac M, Cross H, Trinka E, Walker M. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia. 2008;49:1277–85. doi:10.1111/j.1528-1167.2008.01706_3.x.
11. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249:1452–4.
12. Treiman DM, Meyers PD, Walton NY, Collins IF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792–8.
13. Allredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631–7. Erratum in: N Engl J Med. 2001;345:1860.
14. Silbergleit R, Lowenstein D, Durkalski V, Conwit R. Neurological Emergency Treatment Trials (NETT) Investigators. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52(Suppl 8):S45–7. doi:10.1111/j.1528-1167.2011.03235.x.
15. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, NETT Investigators, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591–600. doi:10.1056/NEJMoa1107494.
16. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59:205–10.
17. Trinka E. What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam? Epilepsia. 2009;50(Suppl 12):S40–3. doi:10.1111/j.1528-1167.2009.02368.x.
18. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51:251–6. doi:10.1111/j.1528-1167.2009.02323.x.
19. Trinka E. The use of valproate and new antiepileptic drugs in status epilepticus. Epilepsia. 2007;48:2383.
20. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52(Suppl 8):S35–8. doi:10.1111/j.1528-1167.2011.03232.x.
21. Höfler J, Unterberger I, Dobsberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52:e148–52. doi:10.1111/j.1528-1167.2011.03233.x.
22. Höfler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54:393–404. doi:10.1111/epi.12058.
23. Barnes SE, Bland D, Cole AP, Evans AR. The use of sodium valproate in a case of status epilepticus. Dev Med Child Neurol. 1976;18:236–8.
24. Vajda FJ, Summington GR, Bladin PF. Rectal valproate in intractable status epilepticus. Lancet. 1977;1:359–60.
25. Vajda FJ, Mihaly GW, Miles JL, Donnan GA, Bladin PF. Rectal administration of sodium valproate in status epilepticus. Neurology. 1978;28:897–9.
26. Viani F, Jussi MI, Germano M, Lotti P, Lotti F. Rectal administration of sodium valproate for neonatal and infantile status epilepticus. Dev Med Child Neurol. 1984;26:678–9.
27. Holle LM, Gidal BE, Collins DM. Valproate in status epilepticus. Ann Pharmacother. 1995;29:1042–4.
28. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695–714.
29. Giroud M, Gras D, Escousse A, Dumas R, Venaud G. Use of injectable valproic acid in status epilepticus. A pilot study. Drug Investig. 1993;5:154–9.
30. Czapinski P, Terczynski A. Intravenous valproic acid administration in status epilepticus. Neurol Neurochir Pol. 1998;32:11–22.
31. Campistol J, Fernandez A, Ortega J. Status epilepticus in children. Experience with intravenous valproate. Update of treatment guidelines. Rev Neurol. 1999;29:359–65.
32. Katragadda S, Chand Aluri B, Burdette D. Intravenous administration of valproate for status epilepticus in 12 patients. Epilepsia. 2000;41:216 (Abstract).
33. Überall MA, Trollmann R, Wünsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000;54:2188–9.
34. Nariotoku DK. Outcome of status epilepticus treated with intravenous valproic acid. Adv Stud Med. 2000;1:279–80.
35. Rosenow F, Knake S. Intravenous Valproinsäuretherapie zur Statusbehandlung. In: Krämer G, Walden J, editors. Valproinsäure. Berlin: Springer; 2002.
36. Jha S, Jose M, Patel R. Intravenous sodium valproate in status epilepticus: a pilot study. Eur J Neurol. 2011;18:1391–6. doi:10.1111/j.1468-1331.2011.03420.x.
37. Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous sodium valproate versus intravenous phenytoin. Epilepsia. 2011;52:394–6.
38. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus—experience in 102 adult patients. Seizure. 2005;14:164–16.
39. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology. 2005;64:353–5.
40. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus—experience in 102 adult patients. Seizure. 2005;14:164–16.
41. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology. 2006;67:340–2.
42. narwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16:527–32.
43. Mehta V, Singh P, Singh S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22:1191–7.
44. Narayanan JT, Murthy JM. Nonconvulsive status epilepticus in a neurological intensive care unit: profile in a developing country. Epilepsia. 2007;48:900–6.
45. Olsen KB, Taubb E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl. 2007;187:51–4.
46. Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B, et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008;118:296–300. doi:10.1111/j.1600-0404.2008.01097.x.
47. Chen L, Peng P, Wang J, Liu L, Zhou D. Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. J Clin Neurosci. 2009;16:524–6. doi:10.1016/j.jocn.2008.06.007.
48. Tiankao S, Savanyawisuth K. Predictors and prognosis of status epilepticus treated with intravenous sodium valproate. Epileptic Disord. 2009;11:228–31. doi:10.1684/epid.2009.0271.
IV Valproate in Status Epilepticus

70. DeWolfe JL, Knowlton RC, Beasley MT, Coifield S, Faught E, Limdi NA. Hyperammonemia following intravenous valproate loading. Epilepsy Res. 2009;85:65–71. doi:10.1016/j.eplepsyres.2009.02.012.

71. Morton LD, O’Hara KA, Coots BP, Pellock JM. Safety of rapid intravenous valproate infusion in pediatric patients. Pediatr Neurol. 2007;36:81–3.

72. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology. 2000;55:722–4.

73. Anderson GD, Lin Y, Temkin NR, Fischer JH, Winn HR. Incidence of intravenous site reactions in neurotrauma patients receiving valproate or phenytoin. Ann Pharmacother. 2000;34:697–702.

74. O’Brien TJ, Cascino GD, So EL, Hanna DR. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol. 2006;13:e5–6.

75. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51:1034–9.

76. Larch J, Trinka E. Intravenous valproate—a systematic review of the incidence of the purple glove syndrome. Epilepsia. 2001;42:1156–9.

77. Rossetti AO, Bromfield EB. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2000;65:500–501; author reply 500-501.

78. Embacher N, Karner E, Wanschitz J, Beer R, Trinka E. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol. 2006;13:e5–6.

79. Burneo JG, Limdi N, Kuzniecky RI, Knowlton RC, Mendez M, Lawn N, et al. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. Neurology. 2003;60:1991–2.

80. White JR, Santos CS. Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. J Child Neurol. 1999;14:822–3.

81. Fernandez-Fernandez FJ, Garcia-Rego J, Garcia-Jimenez A, Sesma P. Hemorrhagic shock and fulminant hepatic failure associated with valproate. An Med Interna. 1995;12:606–8.

82. Larch J, Trinka E. Intravenous valproate—a systematic review of the evidence. Epilepsia. 2006;47(s3):38–9 (Abstract).

83. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord. 2009;2:79–91. doi:10.1177/1756285608100460.

84. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123:137–41. doi:10.1111/j.1600-0404.2010.01423.x.

85. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Trinka E, Shorvon S. The proceedings of the Innsbruck Colloquium on Status Epilepticus. Epilepsia. 2010;51:1111–22. doi:10.1111/j.1528-1167.2010.02353.x.

86. Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP. Comparative effect sizes in randomised studies from less developed and more developed countries: meta-epidemiological assessment. BMJ. 2013;346:f7707.

87. Tan KY, Neligan A, Shorvon SD. The uncommon causes of status epilepticus: a systematic review. Epilepsy Res. 2010;91:111–22. doi:10.1016/j.eplepsyres.2010.07.015.

88. Trinka E, Höller J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012;53(Suppl 4):S127–38. doi:10.1111/j.1528-1167.2012.03622.x.

89. Misra UK, Kalita J, Nair PP. Status epilepticus in central nervous system infections: an experience from a developing country. Am J Med. 2008;121:618–23.

90. Singh G. Other central nervous system infections and status epilepticus. Epilepsia. 2009;50(Suppl 12):S64–6. doi:10.1111/j.1528-1167.2009.02347.x.

91. Newton CR. Status epilepticus in resource-poor countries. Epilepsia. 2009;50(Suppl 12):S34–5. doi:10.1111/j.1528-1167.2009.02364.x.

92. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia. 2000;41:1342–5.

93. Shorvon S. The management of status epilepticus. J Neurol Neurosurg Psychiatry. 2001;70(Suppl 2):II22–27.

94. Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000;54:230–2.

95. Vivekanandan S, Nayak SD. Valproate-induced hyperammonemic encephalopathy enhanced by topiramate and phenobarbital: a case report and an update. Ann Indian Acad Neurol. 2010;13:145–7. doi:10.4103/0997-2327.64638.

96. Chakor RT, Bharate HS. Topiramate-valproate-induced encephalopathy in migraine. Headache. 2012;52:1321–2. doi:10.1111/j.1526-4610.2012.02213.x.

97. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand Suppl. 2006;184:1–13.

98. Trinka E, Shorvon S. The proceedings of the Innsbruck Colloquium on Status Epilepticus. Epilepsia. 2010;51:1111/j.1528-1167.2010.02353.x.

99. Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ. 2013;346:f7707.

100. Aldenkamp A, Vigevano F, Arzimanoglou A, Covani A. Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol Scand Suppl. 2006;184:1–13.

101. Ben-Menachem E, Schmitz B, Tomson T, Vajda F. Role of valproate across the ages. Treatment of epilepsy in adults. Acta Neurol Scand Suppl. 2006;184:14–27.

102. Trinka E, Shorvon S. The proceedings of the Innsbruck Colloquium on Status Epilepticus. Epilepsia. 2010;51:1111/j.1528-1167.2009.02357.x.

103. Cock HR, ESETT Group. Established status epilepticus treatment trial (ESETT). Epilepsia. 2011;52(Suppl 8):S50–2. doi:10.1111/j.1528-1167.2011.02337.x.

104. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, Fountan N, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54(Suppl 6):89–92. doi:10.1111/epi.12288.

105. Grosse P, Rüsch L, Schmitz B. Pancreatitis complicating treatment with intravenous valproic acid. J Neurol. 2002;249:484–5.

106. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:67–74.

107. Strzelski A, Knake S, Oentel WH, Rosenow F, Hamer HM. Inpatient treatment costs of status epilepticus in adults in Germany. Seizure. 2013;22:882–5.